Cardio3 BioSciences appoints Dr Atta Behfar
Published on: 29/07/10
Belgium biotech company Cardio3 BioSciences has appointed Dr Atta Behfar as director for advanced research.
He will spend a year at the company, joining its research and development operations while on assignment from US healthcare institute the Mayo Clinic.
Dr Behfar was a member of the Mayo Clinic’s clinician investigator programme in cardiology and played a key role in the research underlying Cardio3 BioSciences’ lead product, C-Cure, a stem cell treatment for heart failure.
He said: “It is a very exciting time for Cardio3 BioSciences with C-Cure having shown encouraging early results in a clinical setting. I look forward to working with the in-house team as they further advance the product from being a scientific concept towards becoming a therapy that could potentially treat one of the world’s greatest unmet medical needs.
“Many additional treatments may also be leveraged out of the science that lead to C-Cure discovery, and my role will be to fully develop the potential of Cardio3 BioSciences’ unique technology.”
Mission Statement
InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma jobs, pharma events, and pharma service company listings.
Site content is produced by our editorial team for InPharm.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
